Introduction
Tuberculosis is one of the top 10 causes of death worldwide.1 It is the leading killer of people with HIV and a major cause of deaths related to antimicrobial resistance.1 India is the country with the highest burden (27% of global) of Tuberculosis cases.1 According to Global Tuberculosis Report 2018, Tuberculosis incidence in India is 2.74 million including 0.13 million drug resistant cases, According to WHO 0.41 million death in India due to tuberculosis 2017.2
Most easily available diagnostic method i.e. Sputum smear microscopy is facing variable sensitivity issue particularly in patients with sputum smear-negative and/or extrapulmonary disease, and drug-resistant Tuberculosis.3,4,5 With the help of microscopy only 49% of cases can be detected in Madhya Pradesh, India.6 Besides technical expertise and biosafety concerns, Culture on Lowenstein-Jensen (LJ) medium, “the gold standard test”, takes 2-8 weeks to produce growth causing delayed onset of treatment.5 New generation liquid culture diagnostics and molecular line probe assays are costly and needed biosafety measures and specialised staff.3
To overcome this problem, WHO’s current policies and guidance recommend that Xpert MTB/RIF be used as an initial diagnostic test in individuals suspected of having MDR-TB or HIV-associated TB (strong recommendation, moderate quality of evidence).7 The guidance also provides a conditional recommendation that Xpert MTB/RIF be used as a follow-up test to smear microscopy in settings where MDR-TB or HIV are of lesser concern, especially for further testing of smear-negative specimens.7
Materials and Methods
This study done at RNTCP lab, Microbiology Dept., Govt. Medical College Khandwa, M.P., India, is a Retrospective observational record based analysis. The study period is from 01 January 2018 to 31 May 2019 (1 year 5 months). A total of 1993 samples according to inclusion & exclusion criteria mention below were included in this study.
Inclusion criteria
All adult patients above 13 years of age & both sexes.
All clinically suspected cases of pulmonary & extrapulmonary Tuberculosis.
All new & old (including treatment failure, defaulters & relapse) cases of pulmonary & extrapulmonary Tuberculosis.
All pulmonary & extrapulmonary samples received in CBNAAT lab.
Exclusion criteria
TB detection was done by Xpert MTB/ RiF assay, made by Cepheid (Sunnyvale, CA, United States).6 All specimens were processed according to the GeneXpert system operator manual given by Central TB division, Government of India.6 The assay is designed for extraction, amplification and identification of rpoB gene of M. tuberculosis as it accounts for more than 95% of mutations associated with rifampicin resistance.6,7 Xpert MTB/RIF cartridge is a disposable, single self-enclosed test unit in which all steps of NAAT i.e. Sample processing, PCR amplification and detection are automated and integrated.
Results
During study period from 01 January 2018 to 31 May 2019, 1993 samples were received. Out of this, 116 PLHIV samples & 103 pediatrics age group patients samples & 38 invalid test result samples were excluded from our study. So 1736 samples were included in this study. 1537 samples were pulmonary & 199 Extrapulmonary. Sample positivity rate was (727) 41.87%, of which (680) 39.17% Rifampicin sensitive & (47) 2.7% resistant for Mycobacterium tuberculosis as shown in Figure 1. Rifampicin sensitivity in newly treated patient (96.9%) was little high as compare to previously treated patient (89.2%). Rifampicin resistance was high in previously treated patient (10.4%) as compare to newly treated patient (3.1%) as shown in Figure 2.
199 extrapulmonary samples were received during study period. 37 were positive for Mycobacterium tuberculosis, out of this 33 s ensitive & 4 were resistant to Rifampicin. All the four resistant to Rifampicin were found only sensitive to fluoroquinolones. Sample vise distribution is shown in Table 1 but the most common samples were Pleural fluid 43.7%, Pus 27% & cervical lymph node 16.6%.
Figure 1
Percentage distribution of test in accordance to positivity as well as Rifampicin susceptibility
Table 1
Extrapulmonary samples distribution & their sensitivity to Rifampicin
Discussion
Tuberculosis is the major cause of mortality & morbidity in our country.1 CBNAAT shows its utility in paucibacillary Pulmonary & Extrapulmonary MTB infection, where microscopy may be compromised as well as simultaneously Rifampicin resistance detection ability make this test very useful in routine practices.
Total sample positivity by CBNAAT In our study was 41.87%. Gour Sanjay M et al found 17.6% sample positivity in their study.8 Rifampicin resistance by CBNAAT was low 6.47% in our study. Very similar observation (6.38%) found by Gour Sanjay M et al.8 Rifampicin resistance also found 13.55% by D. Pragati Rao et al,9 25% by R Dewan et al10 & very high (53%) by R Tripathi et al11 in their study. Rifampicin sensitivity for positive samples by CBNAAT was 93.53% in our study. Similar observation (93.6%) also found by Gour Sanjay M et al.8 75% sample shown Rifampicin sensitivity in the study done by R Dewan et al10 but R Tripathi et al11 found only 35.8%.
Extrapulmonary samples found to be positive by CBNAAT were 18.59% in our study. Shivprasad Kasat et al also found 15.06% Extrapulmonary samples positivity in their study.12 Pleural fluid (43.7%) was most common extrapulmonary samples followed by Pus (27%) & lymph node (16.6%). Gour Sanjay M et al also found Pleural fluid 49.81% most common sample followed by lymph node 40%, Pus 37.73%.8 Subhakar Kandi et al found lymph node 19% most common sample followed by Pleural fluid & BAL 10% & CSF 2.5%.13
Conclusion
CBNAAT is a very useful tool for diagnosis as well as Rifampicin resistance detection for Mycobacterium tuberculosis. Rifampicin resistant Mycobacterium tuberculosis is low in our area as compare to other part of India give indirect indication of good implementation of RNTCP program in our area.
Article
DOI
